More Antibodies Than Stars: Overhauling Antibody Drug Discovery
Executive Summary
Antiverse co-founder and CEO Murat Tunaboylu, one of In Vivo’s 2022 Rising Leaders, on defining success and why software engineers should consider a career transition to life sciences.
You may also be interested in...
Twist Bioscience: DNA Research Tools Put Fresh Spin On Drug Discovery
Speed and efficiency are fundamental to the success of today’s biopharmaceutical enterprise, but the hunt is still on for transformative technologies to boost pipeline productivity and growth. One answer may lie in the arrival of replicable, synthetic versions of DNA.
How Can Pharma Seek To Discuss Gender Diversity?
As gender-neutral language becomes more widely used throughout the business community, the pharmaceutical industry must confront how it approaches the matter of gendered language in healthcare communications.
Return To Growth In Biosimilars A Priority For Biogen
Biogen’s biosimilars business took a hit in Q1 following pricing pressures and negative currency fluctuations, with the company now prioritizing the rebuilding of the segment.